Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Status Epilepticus
Interventions
Quality improvement bundle, Quality improvement bundle and local PDSA cycles with central support, Quality improvement bundle and local PDSA cycles without central support
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
30 Days to 18 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Status Epilepticus, Refractory Status Epilepticus
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Terminated Phase 3 Interventional Results available

Treatment of Refractory Status Epilepticus

NCT00265616
Conditions
Status Epilepticus
Interventions
propofol, thiopental/pentobarbital
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Neonatal Encephalopathy
Interventions
Epilog device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 30 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Refractory Epilepsy
Interventions
Traditional Treatment (Group T), Ketamine Infusion (Group K)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Interventions
Epidiolex 100 mg/mL Oral Solution, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lake Success, New York
Conditions
Status Epilepticus, Coma
Interventions
Rapid Response EEG
Device
Lead sponsor
Children's Hospital at Montefiore
Other
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Midazolam in Healthy Adults

NCT04679623
Conditions
Status Epilepticus
Interventions
Midazolam, Seizalam
Combination Product · Drug
Lead sponsor
Rafa Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 40 more
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
TBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC), Subarachnoid Hemorrhage, Aneurysmal, Ischemic Stroke, Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 85 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Lexington, Kentucky • Columbus, Ohio
Conditions
Super-refractory Status Epilepticus
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more
Conditions
Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more
Conditions
Seizures
Interventions
Clinically indicated EEG monitoring.
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 18 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
52
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 31 more
Conditions
Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Intraventricular Hemorrhage, Nontraumatic Haemorrhage, Status Epilepticus
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Timeline
2014 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Altered Mental Status, Generalized Nonconvulsive Seizure Disorder, Status-epilepticus
Interventions
Not listed
Lead sponsor
Bio-Signal Group Corp.
Industry
Eligibility
13 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Landau-Kleffner Syndrome, Status Epilepticus, Electrographic
Interventions
Diazepam, Acetazolamide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Status Epilepticus, Electrographic, Coma
Interventions
Vigabatrin Only Product
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Super-Refractory Status Epilepticus
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
100
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more
Completed Phase 3 Interventional Results available

Established Status Epilepticus Treatment Trial

NCT01960075
Conditions
Benzodiazepine Refractory Status Epilepticus
Interventions
Fosphenytoin, Levetiracetam, Valproic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
2 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
65
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more
Conditions
Epilepsy, Status Epilepticus, Seizures
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Albuquerque, New Mexico